Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trialThomas Powles, Alain Ravaud, Syed A. Hussain et al.|The Lancet|2017Cited by 1.4k
ctDNA guiding adjuvant immunotherapy in urothelial carcinomaThomas Powles, Sanjeev Mariathasan, Zoe J. Assaf et al.|Nature|2021Cited by 603
Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancerNamrata S. Patil, David S. Shames, Barzin Y. Nabet et al.|Cancer Cell|2022Cited by 403
LRRC15+ myofibroblasts dictate the stromal setpoint to suppress tumour immunityAkshay T. Krishnamurty, Shannon J. Turley, Justin A. Shyer et al.|Nature|2022Cited by 385
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockadeBarzin Y. Nabet, David S. Shames, Habib Hamidi et al.|Cancer Cell|2024Cited by 154